The Southern Cross Equities report (page 15) on Prana briefly mentioned animal data demonstrating Pbt2 reversing normal age related cognitive impairment, ie normal healthy but aged mice. This data was released at the International Conference of Alzheimer's Disease, July 2009. This is quite amazing data. If this data were replicated in humans Pbt2 would have the potential to be the most lucrative pharmaceutical product in history.
Prana appears is cheap at the moment because management has been conspicuously quiet for 6 months. My feeling is that this is the calm before the storm and that the inertia will be broken soon. How do other Pbt shareholders feel?.
pbt2 potential nootropic agent for the elderly
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(12.5%) |
Mkt cap ! $23.60M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $1.603K | 341.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 60 | 68910222 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 29034580 | 23 |
View Market Depth
| Last trade - 15.59pm 04/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |